
|Videos|April 12, 2022
What’s next for sacral neuromodulation in OAB patients with Parkinson’s disease?
Author(s)Urology Times staff
“I think the take home message is not to take sacral neuromodulation off the table,” says Sarah Martin, DO.
Advertisement
In this video, Sarah Martin, DO, discusses the take-home message from the recent Neurourology & Urodynamics study, “Is sacral neuromodulation effective in patients with Parkinson's disease? A retrospective review,” for which she served as first author. Martin is an FPMRS fellow at Glickman Urological & Kidney Institute at Cleveland Clinic.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












